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Abstract The objective of the study was to examine whether
disease duration independently predicts treatment response
among biologic-naïve patients with rheumatoid arthritis
(RA) initiating abatacept in clinical practice. Using
the Corrona RA registry (February 2006–January 2015),
biologic-naïve patients with RA initiating abatacept with
12-month (±3 months) follow-up and assessment of disease
activity (Clinical Disease Activity Index [CDAI]) at initiation
and at 12 months were identified. The primary outcome was
mean change in CDAI (ΔCDAI) from baseline to 12 months.
Secondary outcomes at 12 months included achievement of
low disease activity (LDA; CDAI ≤10 in patients with
moderate/high disease activity at initiation) and remission
(CDAI ≤2.8 in patients with low, moderate or high disease
activity at initiation). Linear and logistic regression analyses
were performed to examine the relationship between disease
duration and response to abatacept. There were 281 biologic-
naïve patients with RA initiating abatacept (disease duration
0–2 years, n = 107; 3–5 years, n = 45; 6–10 years, n = 50;
>10 years, n = 79). Increased disease duration was associated
with older age (p = 0.047), and the median number of prior
conventional disease-modifying antirheumatic drugs used
was lowest in the 0- to 2-year duration group (p < 0.001).
Mean ΔCDAI (SE) ranged from −10.22 (1.19) for 0–2 years
to −4.63 (1.38) for >10 years. In adjusted analyses, shorter
disease duration was significantly associated with greater
meanΔCDAI (p = 0.015) and greater likelihood of achieving
LDA (p = 0.048). In biologic-naïve patients with RA initiating
abatacept, earlier disease (shorter disease duration) was asso-
ciated with greaterΔCDAI and likelihood of achieving LDA.
Keywords Disease activity . Disease-modifying
antirheumatic drugs (DMARDs) . Non-TNFi biologic .
Outcomemeasures . Registry . Rheumatoid arthritis
Introduction
Rheumatoid arthritis (RA) is a chronic, debilitating, progres-
sive, inflammatory disease characterized by joint inflamma-
tion, which can lead to structural damage [1]. RA has a sig-
nificant impact on patients’ abilities to perform activities of
daily living [2], reduces physical and mental health-related
quality of life, increases healthcare utilization and is associat-
ed with increased mortality [1]. The goal of RA therapy is to
reduce disease activity, prevent long-term sequelae and im-
prove functional status [2]. The treat-to-target paradigm is
being widely advocated, specifically treatment acceleration
in patients with active disease. The goal of this treatment
paradigm is to achieve remission or, if remission is unattain-
able, low disease activity (LDA), based on validated outcome
measures. Furthermore, it has been postulated that there is a
‘window of opportunity’ in early RA, during which treatment
could alter the disease course before the inflammatory and
autoimmune processes become established, irreversible dam-
age has occurred and patients become increasingly refractory
to treatment [3, 4]. Supporting this theory, patients with RA of
longer disease duration generally do not respond as well to
treatment with a biologic disease-modifying antirheumatic
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drug (bDMARD) as those with a shorter duration of disease
[3]. Consequently, patients treated earlier have improved dis-
ease control and better outcomes compared with patients treat-
ed later in the disease course [4, 5].
Abatacept is a selective T-cell costimulation modulator
available in intravenous and subcutaneous formulations and
is indicated for the treatment of RA and juvenile idiopathic
arthritis. The efficacy of abatacept has been demonstrated in
patients naïve to methotrexate (MTX) or biologic therapy [5],
as well as in treatment-experienced patients with an inade-
quate response to prior therapy with MTX [6] or tumour ne-
crosis factor-α (TNF) inhibitors [7]. An exploratory post hoc
analysis of pooled data from two abatacept trials in biologic-
naïve patients with an inadequate response to MTX demon-
strated that a higher percentage of patients with early RA
(<2 years) achieved an American College of Rheumatology
(ACR)70 response, Disease Activity Score in 28 joints
(DAS28) (C-reactive protein) remission and clinically mean-
ingful improvement in the Health Assessment Questionnaire
(HAQ)-Disability Index versus patients with long-standing
disease (>10 years) [8]. This relationship between disease du-
ration and treatment response to abatacept in patients with RA
has not been explored in patients cared for in routine clinical
practice.
The objective of this analysis was to examine whether dis-
ease duration is an independent predictor of treatment re-
sponse among biologic-naïve patients with RA initiating
abatacept in a US national cohort.
Patients and methods
Patient population
The Corrona registry collects and analyses treatment and out-
comes data for patients with chronic rheumatologic and der-
matologic diseases. The Corrona RA registry is an indepen-
dent, prospective, national, observational cohort study.
Patients are recruited from 168 private and academic practice
sites across 40 states in the USA, with 654 participating rheu-
matologists. As of 31 March 2016, the Corrona database in-
cluded information on approximately 42,621 patients with
RA. Data on 321,001 patient visits and approximately
141,984 patient-years of follow-up observation time have
been collected. This study was carried out in accordance with
the Declaration of Helsinki. All participating investigators
were required to obtain full board approval for conducting
non-interventional research involving human subjects with a
limited dataset. Sponsor approval and continuing review was
obtained through a central Institutional Review Board (IRB;
New England Independent Review Board, NEIRB No.
120160610). For academic investigative sites that did not re-
ceive a waiver to use the central IRB, full board approval was
obtained from the respective governing IRBs and documenta-
tion of approval was submitted to Corrona, LLC prior to ini-
tiating any study procedures. All registry patients were re-
quired to provide written informed consent and authorization
prior to participating.
Study population
This analysis included patients with RA >18 years of age who
were biologic naïve and who had started treatment with
abatacept during follow-up in the Corrona RA registry be-
tween February 2006 and January 2015. Eligible patients
had to have a follow-up visit at 12 months (±3 months) after
the initiation of treatment (using the visit closest to 12 months
if there was >1 visit) and Clinical Disease Activity Index
(CDAI) measured at or prior to the initiation of treatment. If
the physician reported a treatment start date, CDAI score was
measured within 4 months prior to initiation. If the physician
did not report a start date for treatment, disease activity from
the prior visit was used if this visit was within 6 months of the
date of initiation. Other inclusion criteria were measurement
of CDAI score at 12 months (±3 months) or at the time of
switch if this occurred prior to the 12-month visit and no prior
bDMARD use.
Assessments and data collection
Patient demographics, baseline characteristics and clinical
outcomes were assessed across four disease duration groups
(0–2, 3–5, 6–10, >10 years). Disease duration was collected
from the rheumatologist based on the year of RA onset and the
visit of initiation. Data were collected from patients and their
treating rheumatologists using standard clinical research
forms at the time of the clinical encounter. These forms gather
information on disease severity and activity (including com-
ponents of ACR response criteria), medical comorbidities, use
of medications including conventional (c)DMARDs and ad-
verse events. Data elements collected in the registry that were
relevant to this study included components of CDAI (swollen
joint count, 28 tender joint count, physician global assessment
and patient global assessment), patient assessment of pain,
DAS28 (erythrocyte sedimentation rate; ESR) and the modi-
fied (m)HAQ assessing physical function [9]. Data on demo-
graphics, insurance status, comorbid conditions, RA disease
characteristics and RA medications were available for >98%
of patients. The scope of the data collected and comparison
with other registries have been previously described [10].
Study outcomes
The primary outcome was mean change in CDAI (ΔCDAI) at
12 months (CDAI score at 12 months minus CDAI score at
initiation). The secondary outcomes were achievement of
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LDA (CDAI score ≤10) among patients who initiated
abatacept with moderate or high disease activity and achieve-
ment of remission (CDAI score ≤2.8) in those who initiated
abatacept with low, moderate or high disease activity.
Discontinuations and switching status were also examined.
Patients were categorized into one of three mutually exclusive
groups: those who switched from abatacept to a new biologic,
those who discontinued abatacept without initiating a new
biologic before their 12-month visit and those who remained
on abatacept until their 12-month visit.
Statistical analysis
Baseline characteristics of patients in the different disease du-
ration groups were compared using descriptive statistics. A
two-sided 5% significance level was used to assess statistical
differences. For patients who switched agents before
12 months, the last observation before the switch was used
to calculate mean ΔCDAI. Switchers were imputed as non-
responders for calculation of LDA and remission. For patients
who discontinued an agent and did not start another before
12 months and those who continued on their original agent
through their 12-month visit, measurement at the 12-month
visit was used to calculate outcomes. Mean ΔCDAI from
baseline was calculated by disease duration group. The rates
of LDA/remission and remission at 12 months by disease
duration group were estimated (unadjusted). p values were
based on omnibus tests of any differences in the duration
groups. Fisher’s exact test was used when there were small
counts, as for switching status. Multivariable linear regression
models were fit to assess the association of ΔCDAI from
baseline by disease duration group. Multivariable logistic re-
gression models were conducted to assess the association of
disease duration and LDA/remission and remission at
12 months. Baseline characteristics that were indicative of a
difference (p < 0.1) across the disease duration groups, as well
as characteristics that were chosen a priori by investigators
(age, sex, baseline CDAI score and number of prior
cDMARDs), were used as covariates in the models. Of note,
MTX use did not meet criteria for inclusion in the adjusted
models. However, as MTX use may influence results, we re-
ran the above-mentioned adjusted models with the addition of
MTX. The results were unchanged (data not shown) from the
original models and thus are not included in this manuscript.
Results
Patient disposition and baseline characteristics
There were a total of 281 abatacept initiators whowere biologic
naïve and met the inclusion criteria (disease duration 0–2 years,
107 [38.1%]; 3–5 years, 45 [16.0%]; 6–10 years, 50 [17.8%];
>10 years, 79 [28.1%]). In general, baseline characteristics
were similar across the four disease duration groups
(Table 1), with a similar percentage of female patients (76–
89%) and similar distributions for level of education, comorbid
conditions, smoking status and morning stiffness. The average
weight, body mass index, blood pressure and most of the dis-
ease activity measures including CDAI, DAS28 (ESR), patient
pain, mHAQ and patient-reported fatigue were also similar
across the disease duration groups. Patients with disease dura-
tion >10 years were older (median [IQR] 67 [16] years), were
on average younger at onset of RA (mean [SD] 46.5
[13.2] years) and had higher prior cDMARD use (median
[IQR] of 2 [2]) versus patients in other disease duration groups.
Efficacy
The results for the primary and secondary efficacy outcomes are
presented in Table 2. In the unadjusted analysis, the greatest
ΔCDAI from baseline occurred in the group of patients with
the shortest disease duration (0–2 years: mean ΔCDAI [SE]:
−10.22 [1.19]) and the smallest change occurred in the group
with the longest disease duration (>10 years; −4.63 [1.38]; over-
all p = 0.017). Response rates for the binary outcomes of LDA
and remission did not differ significantly according to disease
duration group (p = 0.21 and 0.23, respectively; Table 2).
After adjustment for age, sex, baseline CDAI score and prior
number of cDMARDs used, the significant difference between
the disease duration groups inΔCDAI from baseline remained
(0–2 years, meanΔCDAI [SE], −9.65 [1.02]); >10 years, −4.58
[1.19]; overall p = 0.015). In addition, there was a significant
difference in achievement of LDA across the four groups, with
the group of patients with disease duration of 0–2 years being
nearly three times as likely to reach LDA at 12 months follow-
ing abatacept initiation as the group with >10 years of disease
duration (odds ratio [95% confidence interval] 2.76 [1.28,
5.97]; p = 0.048). Similarly, those with 0–2 years of disease
duration were three times more likely to achieve remission at
12 months than those with >10 years of disease duration (odds
ratio [95% confidence interval] 3.12 [1.30, 7.46]; p = 0.055). Of
note, the proportion of patients who remained on abatacept at
12months was similar across the disease duration groups, rang-
ing from 67 to 74% (p = 0.60; Table 3).
Discussion
In biologic-naïve patients with RA, unadjusted modelling re-
vealed a significant difference inΔCDAI from baseline between
patients with shorter versus longer disease duration. However,
unadjusted response rates for LDA and remission were similar
between disease duration groups. ΔCDAI from baseline
remained significant in the multivariable model adjusted for

















Female sex, n (%) 88 (82.2) 34 (75.6) 39 (78.0) 70 (88.6) 0.24
Age, years, median (IQR) 61.0 (21) 65.0 (18) 64.5 (15) 67.0 (16) 0.047
Duration of RA, median (IQR) 1.0 (1) 4.0 (1) 8.0 (3) 19.0 (14) <0.001
Age at onset, years, mean ± SD 59.0 ± 14.0 57.6 ± 13.6 55.8 ± 11.6 46.5 ± 13.2 <0.001
Race, n (%) 0.018
White 91 (85.0) 29 (64.4) 40 (80.0) 62 (80.5)b
Hispanic 8 (7.5) 10 (22.2) 5 (10.0) 12 (15.6)b
African-American 5 (4.7) 6 (13.3) 1 (2.0) 3 (3.9)b
Asian 2 (1.9) 0 2 (4.0) 0
Other 1 (0.9) 0 2 (4.0) 0
Smoking status, n (%)c 0.23
Never 52 (50.0) 25 (55.6) 22 (44.0) 45 (57.0)
Previous 40 (38.5) 12 (26.7) 18 (36.0) 29 (36.7)
Current 12 (11.5) 8 (17.8) 10 (20.0) 5 (6.3)
Weight, lbs., median (IQR) 164 (53) 166 (45) 174 (48) 163 (49) 0.35
Work status, n (%) 0.002
Full time 43 (40.2) 10 (22.2) 12 (24.0) 16 (20.3)
Part time 15 (14.0) 9 (20.0) 4 (8.0) 5 (6.3)
Not working outside home 13 (12.1) 6 (13.3) 5 (10.0) 3 (3.8)
Student 1 (0.9) 1 (2.2) 0 2 (2.5)
Disabled 4 (3.7) 6 (13.3) 8 (16.0) 12 (15.2)
Retired 31 (29.0) 13 (28.9) 21 (42.0) 41 (51.9)
Number of prior cDMARDs (including current
cDMARD), median (IQR)
1 (1) 2 (1) 2 (1) 2 (2) <0.001
Presently on MTX, n (%) 78 (72.9) 30 (66.7) 28 (56.0) 56 (70.9) 0.19
Comorbid conditions, n (%)
Hypertension 38 (35.5) 17 (37.8) 19 (38.0) 38 (48.1) 0.36
Diabetes 9 (8.4) 4 (8.9) 5 (10.0) 4 (5.1) 0.73
Malignancyd 14 (13.1) 2 (4.4) 7 (14.0) 11 (13.9) 0.39
CV disease 5 (4.7) 2 (4.4) 3 (6.0) 8 (10.1) 0.45
Serological status
CCP positive, n (%)e 25 (55.6) 8 (66.7) 11 (73.3) 14 (73.7) 0.43
RF positive, n (%)f 35 (71.4) 18 (85.7) 17 (63.0) 37 (74.0) 0.37
CDAI score, median (IQR)g 18 (16.5) 12.5 (19.5) 12.5 (17) 13 (16.9) 0.13
Patient pain (0–100), median (IQR)h 40 (45) 30 (40) 35 (35) 32.5 (50) 0.70
DAS28 (ESR), median (IQR)i 4 (1.9) 3.6 (3.3) 4.3 (1.5) 3.9 (2.1) 0.90
Patient-reported fatigue (0–100), median (IQR)j 40 (55) 35 (55) 55 (50) 40 (55) 0.92
mHAQ, median (IQR)k 0.25 (0.69) 0.13 (0.63) 0.38 (0.50) 0.25 (0.63) 0.55
Morning stiffness, n (%) 0.30
None 25 (23.4) 10 (22.2) 10 (20.0) 25 (31.6)
<1 h 29 (27.1) 17 (37.8) 12 (24.0) 25 (31.6)
≥1 h 53 (49.5) 18 (40.0) 28 (56.0) 29 (36.7)
CDAI Clinical Disease Activity Index, cDMARD conventional disease-modifying antirheumatic drug, CV cardiovascular,
DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, IQR interquartile range,mHAQmodified
Health Assessment Questionnaire, MTX methotrexate, RA rheumatoid arthritis, SD standard deviation
a p values were from Wilcoxon rank sum tests in the case of comparing medians across the duration groups. When only
means are reported, analysis of variance was used to compare means across the duration groups
b n = 77
c n = 104, n = 45, n = 50 and n = 79, respectively
d History of malignancy includes history of lung cancer, breast cancer, skin cancer (includes melanoma, basal and
squamous cell skin cancer), lymphoma or other cancer
e n = 45, n = 12, n = 15 and n = 19, respectively
f n = 49, n = 21, n = 27 and n = 50, respectively
g n = 107, n = 45, n = 49 and n = 79, respectively
h n = 107, n = 45, n = 50 and n = 78, respectively
i n = 60, n = 18, n = 22 and n = 30, respectively
j n = 77, n = 27, n = 26 and n = 46, respectively
k n = 104, n = 43, n = 50 and n = 79, respectively
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Furthermore, the relationship between disease duration and
achievement of LDAwas statistically significant, while remission
was borderline significant in the adjusted models.
Disease duration has been identified as a predictor of treat-
ment response in patients with RA in both this manuscript and
other publications [3], highlighting the importance of early treat-
ment with both cDMARDs and bDMARDs to achieve remis-
sion or LDAwhen remission is not attainable [11]. Our results
are similar to those from other studies that demonstrated that
earlier treatment with non-bDMARDs or TNF inhibitors was
associated with a greater likelihood of remission [12, 13].
Some interventional trials reported that earlier treatment with
abatacept is associated with better outcomes [8, 14], although
one post hoc analysis found no association between disease
duration and response [15]. The difference in these findings
may reflect variations between trials in disease duration (e.g.
patients with early RA versus patients with established RA)
and treatment history (e.g. biologic naïve versus biologic expe-
rienced,MTX responders versus those with an inadequateMTX
response and TNF-inhibitor responders versus non-responders).
These results, showing a greater benefit in patients with shorter
disease duration at treatment initiation, are consistent with the
proposed early window of opportunity during which there is
potential to alter the disease course in early RA,which otherwise
becomes diminished as the disease becomes established [1].
Earlier treatment is generally accepted to be associated with
improved long-term outcomes. Communication with patients
about the long-term goals of therapy is critical given the apparent
window of opportunity for altering the disease course. Therefore,
physicians need to educate patients on the treat-to-target para-
digm, the ACR treatment guidelines and the benefits of escalat-
ing therapy until remission or LDA is achieved, particularly early
in the disease course as this can improve long-term outcomes [2].
Registry studies provide valuable data on treatment outcomes in
a large cohort of patients in the real-world setting. This analysis
of patients in a US registry provides further long-term (exceeding
10 years in some patients) evidence to support early initiation of a
biologic therapy, in this case, abatacept.
A strength of this study is that it is the largest national US
registry in RA that contains both patient- and provider-reported
measures. As with any observational study, there are limitations.
For example, patients were not randomly assigned to the disease
Table 2 Primary and secondary efficacy outcomes
Outcomes 0–2 years, n = 107 3–5 years, n = 45 6–10 years, n = 50 >10 years, n = 79 p
Unadjusted outcomes
Mean ΔCDAI from baseline (95% CI) −10.22 (−12.55, −7.89) −7.82 (−11.41, −4.24) −6.16 (−9.56, −2.76) −4.63 (−7.34, −1.92) 0.017
Achievement of LDA,a n/N (%) 53/91 (58.2) 17/32 (53.1) 15/33 (45.5) 23/56 (41.1) 0.21
Achievement of remission,b n/N (%) 29/103 (28.2) 11/40 (27.5) 12/48 (25.0) 11/72 (15.3) 0.23
Adjusted outcomesc
Difference in mean ΔCDAI from
baseline (95% CI)
5.07 (1.88, 8.26) 4.03 (0.19, 7.86) 2.19 (−1.45, 5.83) Reference 0.015
Achievement of LDA,a OR (95% CI) 2.76 (1.28, 5.97) 2.44 (0.92, 6.51) 1.36 (0.53, 3.49) Reference 0.048
Achievement of remission,b OR (95% CI) 3.12 (1.30, 7.46) 2.65 (0.97, 7.28) 1.76 (0.67, 4.62) Reference 0.055
ΔCDAI change in CDAI, cDMARD conventional disease-modifying antirheumatic drug, CDAI Clinical Disease Activity Index, CI confidence interval,
LDA low disease activity, OR odds ratio
a CDAI ≤10 among those with moderate or high disease activity
b CDAI ≤2.8 among those with low, moderate or high disease activity
c Adjusted for age, sex, baseline CDAI and number of prior cDMARDs used
Table 3 Abatacept status at










Remained on abatacept at
12 months
79 (73.8) 30 (66.7) 35 (70.0) 57 (72.2)
Discontinued abataceptb 13 (12.1) 6 (13.3) 10 (20.0) 14 (17.7)
Switched from abataceptc 15 (14.0) 9 (20.0) 5 (10.0) 8 (10.1)
Values are n (%)
a Fisher’s exact test
b Discontinuation of abatacept without a new biologic started
c Discontinuation with a new biologic started
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duration groups, so there could have been unmeasured differ-
ences between the cohorts. To attempt to address this, we have
focused on a homogeneous group of biologic-naïve patients only.
In conclusion, these results show that, in a typical US clin-
ical practice setting, abatacept was effective in biologic-naïve
patients with RA who had a range of disease durations at
treatment initiation. However, the magnitude of the response
to abatacept, including reduction in disease activity and
achievement of LDA/remission, was greater in patients with
shorter versus longer disease duration.
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